AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02048852 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced Nicotine Content- Non Menthol
Description: Switch from own brand of cigarette to a research cigarette with a Reduced Nicotine Content of 0.07mg nicotine yield without menthol.
Study NCT02048852 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced Nicotine Content- Menthol
Description: Switch from own brand of cigarette to Reduced nicotine level of each research cigarette to 0.07mg nicotine yield with Menthol
Study NCT02048852 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Nicotine Content- Menthol
Description: Allow own brand of Conventional Nicotine-Menthol Cigarette
Study NCT02048852 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Nicotine Content- Non Menthol
Description: Switch from own cigarette to a research cigarette which contains Conventional Nicotine yield.
Study NCT03420157 — intervention group
Intervention type: OTHER
Intervention: Focus Group
Description: Focus Group of 2 hours. Women will be asked to give their opinion about the communication media of the vaginal self-sampling kit.
Study NCT01691079 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ipratropium bromide
Description: Inhaled ipratropium bromide administered before exercise.
Study NCT01691079 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhaled placebo administered before exercise.
Study NCT00274469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant
Description: 500 mg intramuscular injection
Study NCT00274469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anastrozole
Description: 1 mg oral tablet
Study NCT02139436 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FES-row-training
Study NCT02139436 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Arms-only-row training
Study NCT03296072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.254% w/w sodium fluoride and 5% KNO3
Description: Dentifrice containing 0.254% w/w sodium fluoride (1150 ppm fluoride) and 5% KNO3; plus 0.25% PVM/MA copolymer and 2.5% sodium lactate. Participants will brush it on the buccal surfaces of their natural teeth for 25 timed seconds and then swish the resulting toothpaste slurry around the mouth, without further brushing, for a timed period of 95 seconds. After expectorating the slurry, the participants will gently rinse their mouths with 15 millilitres \[mL\] of tap water for 10 seconds before expectorating again.
Study NCT03296072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.454% w/w stannous fluoride
Description: Dentifrice containing 0.454% w/w stannous fluoride (1100 ppm fluoride). Participants will brush it on the buccal surfaces of their natural teeth for 25 timed seconds and then swish the resulting toothpaste slurry around the mouth, without further brushing, for a timed period of 95 seconds. After expectorating the slurry, the participants will gently rinse their mouths with 15 mL of tap water for 10 seconds before expectorating again.
Study NCT03296072 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5% KNO3
Description: Fluoride free placebo dentifrice containing 5% KNO3 (0 ppm fluoride), 0.25% PVM/MA copolymer and 2.5% lactate. Participants will brush it on the buccal surfaces of their natural teeth for 25 timed seconds and then swish the resulting toothpaste slurry around the mouth, without further brushing, for a timed period of 95 seconds. After expectorating the slurry, the participants will gently rinse their mouths with 15 mL of tap water for 10 seconds before expectorating again.
Study NCT02139436 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Time Control
Study NCT03440346 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Few-foods diet
Description: The few-foods diet (FFD) is followed for 5-weeks preceded by a 1-week transition period during which the child's eating pattern will be gradually adjusted. The diet consists of rice, meat (turkey and lamb), a range of vegetables, pear, rice milk with added calcium and water, and is complemented with foods such as potatoes, fruits, corn, some sweets and wheat, which are allowed in small quantities only. Normal quantities of vegetables, rice and meat are allowed every day. If necessary the diet will be adjusted to avoid foods that the child dislikes or has cravings for. If the child does not respond to the initial FFD, i.e. no change in behaviour after the first two weeks, interim adjustments to the FFD will be made in consultation with the parents.
Study NCT00767793 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One drop in each eye every 12 hours for seven days
Study NCT00767793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INS117548
Description: One drop of Concentration #1 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
Study NCT00767793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INS117548
Description: One drop of Concentration #2 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
Study NCT00767793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INS117548
Description: One drop of Concentration #3 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
Study NCT03418220 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: blood and aqueous humor sampling
Description: The blood sample will be centrifuged. The plasma will be recovered. Plasma and aqueous humor will be frozen and stored at -80° Celsius. The search of 27 markers of inflammation will be performed by the kit LUMINEX Bio-rad (Bio-Rad, M500KCAF0Y).
Study NCT04139434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP-108
Description: For the dose escalation phase, LP-108 will be given once daily at the following dose levels: 100 mg QD, 200 mg QD, 400 mg QD, 600 mg QD, 800 mg QD, 1000 mg QD.
Study NCT02482792 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Norwegian Psychomotor Physiotherapy
Description: The recruited patients will after randomization receive either Norwegian Psychomotor Physiotherapy (NPMP) or COPE combined with active individual physiotherapy. In NPMP the treatment is individualized, targeting body-mind awareness through exercise, massage and therapeutic conversation
Study NCT02482792 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Patient Education and PT
Description: The comparison group will receive a combination of education about how to manage pain (COPE) followed by active individual physiotherapy.
Study NCT04369872 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microwave ablation
Description: Microwave ablation of lung lesion using Solero Microwave Tissue Ablation system.
Study NCT02019004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Onabotulinum Toxin A
Study NCT02019004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Incobotulinum Toxin A
Study NCT02797769 — intervention group
Intervention type: DRUG
Intervention: Other Biologics
Description: Exposure data will be gathered from claims databases, and no medicine will be administered in this non-interventional study. There are no protocol-specified biologic agents, although the analyses will be stratified by TNFi and non-TNFi targeted therapies. The drug selection and regimen are at the discretion of the prescribing physician.
Study NCT02797769 — intervention group
Intervention type: DRUG
Intervention: Tocilizumab
Description: Tocilizumab exposure data will be gathered from claims databases, and no medicine will be administered in this non-interventional study. The regimen is at the discretion of the prescribing physician.
Study NCT04819867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propolis
Description: propolis is an extract derived from bee hives
Study NCT04819867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gluma Desensitizer
Description: Gluma is a desensitizer agent
Study NCT02812108 — intervention group
Intervention type: DEVICE
Intervention: intracranial stent, flow diverter and coils
Study NCT03547349 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Digital Incentive Spirometer
Description: This device is an incentive spirometer connected to a tablet interface. This tablet device uses a digital interface to mimic the look and function of the standard issue incentive spirometer
Study NCT03547349 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital Incentive Spirometer
Description: This device is an incentive spirometer connected to a tablet interface. This tablet device uses a digital interface to mimic the look and function of the standard issue incentive spirometer
Study NCT03547349 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jamboxx Respiratory Therapy Device
Description: THe Jamboxx Respiratory Therapy Device is a novel device that uses interactive gaming to encourage patient compliance with their prescribed respiratory therapy routines. The device consists of a computer game controller with mouthpiece, and breath flow sensor that connects to a tablet. With the Jamboxx Respiratory Therapy Device, users can choose from a suite of breath controlled respiratory therapy games to guide them through their routines while receiving real-time feedback, and long-term progress tracking.
Study NCT02030093 — intervention group
Intervention type: BEHAVIORAL
Intervention: Telephone-based counseling
Description: Telephone-based continuing care wil be provided to patients in different frequency
Study NCT01237223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren/Amlodipine 150/2.5 mg
Description: Aliskiren/amlodipine 150/2.5 mg tablet
Study NCT01237223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren/amlodipine 150/5 mg
Description: Aliskiren/amlodipine 150/5 mg tablet
Study NCT01237223 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aliskiren 150 mg
Description: Aliskiren 150 mg tablet
Study NCT01237223 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine 2.5 mg
Description: Amlodipine 2.5 mg capsule
Study NCT01237223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of Aliskiren
Description: Aliskiren placebo tablet
Study NCT01237223 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of Aliskiren
Description: Aliskiren placebo tablet
Study NCT01237223 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Aliskiren
Description: Aliskiren placebo tablet
Study NCT01237223 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of Amlodipine
Description: Amlodipine placebo capsule
Study NCT01237223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of Amlodipine
Description: Amlodipine placebo capsule
Study NCT01237223 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Amlodipine
Description: Amlodipine placebo capsule
Study NCT01237223 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of Aliskiren/amlodipine 150/2.5 mg
Description: Aliskiren/amlodipine 150/2.5 mg placebo tablet
Study NCT01237223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of Aliskiren/amlodipine 150/2.5 mg
Description: Aliskiren/amlodipine 150/2.5 mg placebo tablet
Study NCT01237223 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Aliskiren/amlodipine 150/2.5 mg
Description: Aliskiren/amlodipine 150/2.5 mg placebo tablet
Study NCT01237223 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of Aliskiren/amlodipine 150/5 mg
Description: Aliskiren/amlodipine 150/5 mg placebo tablet
Study NCT01237223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of Aliskiren/amlodipine 150/5 mg
Description: Aliskiren/amlodipine 150/5 mg placebo tablet
Study NCT01237223 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Aliskiren/amlodipine 150/5 mg
Description: Aliskiren/amlodipine 150/5 mg placebo tablet
Study NCT04587895 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VITAAL Exergame
Description: 12 weeks training with the VITAAL Exergame. The VITAAL exergame is an individualized multicomponent exergame training based mostly on the prevention and slowing of physical and cognitive decline and its consequences. It mainly consists of three (four with UI) components; strength training, balance training, cognitive training and pelvic floor muscle training (PFMT) when suffering from UI.
Study NCT04587895 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Training UI
Description: 12 weeks non-individualized conventional training with a training booklet and additional walking exercise. The PFM training booklet is based on exercises that showed a reduction of incontinence in older adults while performing group pelvic floor muscle training (PFMT) and mobility exercises.
Study NCT04587895 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Training MI
Description: 12 weeks non-individualized conventional training with a training booklet and additional walking exercise. The exercises are based on recommendations from the Beratungsstelle für Unfallverhütung (bfu).
Study NCT00044694 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 0.01 mL
Description: 2-week placebo lead-in period (0.01 mL) followed by 4 weeks of Placebo 0.01 mL subcutaneously injected twice daily
Study NCT00044694 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 0.02 mL
Description: 2-week placebo lead-in period (0.01 mL) followed by 4 weeks of Placebo 0.02 mL subcutaneously injected twice daily
Study NCT00044694 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 0.03 mL
Description: 2-week placebo lead-in period (0.01 mL) followed by 4 weeks of Placebo 0.03 mL subcutaneously injected twice daily
Study NCT00044694 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 0.04 mL
Description: 2-week placebo lead-in period (0.01 mL) followed by 4 weeks of Placebo 0.04 mL subcutaneously injected twice daily
Study NCT00044694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC2993 2.5 mcg
Description: 2-week placebo lead-in period (0.01 mL) followed by 4 weeks of AC2993 2.5 mcg (0.01 mL) subcutaneously injected twice daily
Study NCT00044694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC2993 5.0 mcg
Description: 2-week placebo lead-in period (0.01 mL) followed by 4 weeks of AC2993 5.0 mcg (0.02 mL) subcutaneously injected twice daily
Study NCT00044694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC2993 7.5 mcg
Description: 2-week placebo lead-in period (0.01 mL) followed by 4 weeks of AC2993 7.5 mcg (0.03 mL) subcutaneously injected twice daily
Study NCT00044694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC2993 10.0 mcg
Description: 2-week placebo lead-in period (0.01 mL) followed by 4 weeks of AC2993 10.0 mcg (0.04 mL) subcutaneously injected twice daily
Study NCT02210455 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strongest Families FASD intervention
Study NCT02210455 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Study NCT02210455 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Study NCT04139434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP-108 and azacitidine
Description: For the dose escalation phase, LP-108 will be given once daily at the following dose levels: 100 mg QD, 200 mg QD, 400 mg QD, 600 mg QD, 800 mg QD, 1000 mg QD, with azacitidine at the standard dose of 75 mg/m2 on Day 1 - Day 7 of each 28-day cycle (weekly schedule) or on Days 1-5, 8, 9 of each 28-day cycle (5-2-2 schedule), according to institutional guidelines.
Study NCT01070706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel,Gemcitabine,Sunitinib
Description: To determine the MTD, only DLT occurring during the first cycle of treatment will be considered. And MTD is defined as the dose level at which at least one-third of patients experience a DLT during their first treatment course. The recommended dose level for the subsequent phase II study is defined as the preceding dose level before the MTD is attained.~If MTD is not reached, the recommended initial dose of the phase II part will be at the dose of paclitaxel 80 mg/m2 and gemcitabine 1200 mg/m2 (days 1, 8) with sunitinib 37.5 mg qd D2-D15.
Study NCT02738346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Intravenous administration of Carboplatin AUC 5 at Day 1, Every 3 weeks, maximum 6 cycles
Study NCT02738346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Intravenous administration of 100mg/m²/day of Etoposide, Day 1 to Day 3 Every 3 weeks, maximum 6 cycles
Study NCT02738346 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: Per os administration of 2.3 mg / m2 of Topotecan, Day 1 to Day 5 Every 3 weeks, maximum 6 cycles
Study NCT02738346 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CT scans
Description: The CT scan evaluations will be conducted during chemotherapy every 6 weeks
Study NCT02738346 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CT scans
Description: The CT scan evaluations will be conducted during chemotherapy every 6 weeks
Study NCT04510155 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Overnight fasting duration
Description: Subjects will adhere to overnight fasting protocol for 1 day
Study NCT04487418 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electro cautery surgery
Description: Pre-anesthetics with therapeutic topic (benzocaine) will be administered and, as an anesthetic, or use of anesthetic drops (benzocaine or tetracaine) or local infiltrative anesthesia (2% lidocaine 1: 100,000 with adrenaline).~The surgery will be carried out with cauterization for incision of the lingual brake, division of the brake fibers and release, removing the brake fibers that are stored in the anterior ventral free parts of the tongue until reaching the base of the tongue, which are removed or cleaned, lingual movement, and the anterior axis of the tongue is repositioned or lingual brake in that region. No sutures will be performed and should be oriented on the formation of a pseudo-membranous repair plate in the second intention that will be formed between the first and the third day after surgery.~Postoperative care:~Guidance will be given to the person responsible for not bringing objects to the mouth that may hurt.
Study NCT04487418 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High power diode laser surgery
Description: Pre-anesthetics with therapeutic topic (benzocaine) and as anesthetic or use of anesthetic eye drops (benzocaine or tetracaine) or local infiltrative anesthesia (2% lidocaine 1: 100,000 with adrenaline) will be administered. The surgery will be performed with a high power diode laser (TW Surgical, MMOptics - São Carlos - Brazil). 808 nm wavelength, which can be operated in continuous or interrupted mode. Wattages from 1 to 1.5 W, up to a maximum of 2 W, can be used and must carefully respect the histological characteristics of the target tissue and the signs of overheating and carbonization, so that the choice of parameters is dynamic and very dependent on experience, mastery and care for the operator.~Preoperative care: Guidance will be given to the person responsible for not bringing objects to the mouth that may hurt.
Study NCT01748006 — intervention group
Intervention type: OTHER
Intervention: Standard of care therapy for severe decompensated heart failure
Study NCT01366534 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Crucell's replication deficient adenovirus type 35 circumsporozoite malaria vaccine (Ad35.CS.01)
Description: One dose will be administered intramuscularly at Study Day 0.
Study NCT01366534 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' malaria vaccine 257049 (2 doses)
Description: Two doses will be administered intramuscularly at monthly intervals
Study NCT01366534 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' malaria vaccine 257049 (3 doses)
Description: Three doses will be administered intramuscularly at monthly intervals
Study NCT01366534 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sporozoite challenge
Description: Subjects were challenged with sporozoite-infected mosquitoes to determine whether immune protective response had been induced by vaccination.
Study NCT03959345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination therapy group
Description: Adult patients with MSSA bacteraemia will be randomized to Combination therapy group: patients will receive intravenous cloxacillin 2g/4h and fosfomycin 3 g/6h for the duration of 7 days treatment. After the first week, antibiotic treatment and duration will be decided by responsible clinician following clinical practice.
Study NCT03959345 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy group
Description: Adult patients with MSSA bacteraemia will be randomized to Standard therapy group: patients will receive intravenous cloxacillin 2g/4h for the duration of 7 days IV treatment. After the first week, antibiotic treatment and duration will be decided by responsible clinician following clinical practice.
Study NCT01695460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D3 Vitamin ®
Description: Vitamin D and placebo supplied as tablets in containers of 124. The containers must be kept in dry and not too hot environment.~All subjects randomized to vitamin D, will receive 100 micrograms of vitamin D3/day, equivalent to 4000 IU. Vitamin D is administered orally 1 time a day with breakfast.
Study NCT01695460 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo